Staphylococcus aureus infections are a significant cause of morbidity and mortality in health care settings. S. aureus clinical isolates vary in the function of the accessory gene regulator (agr), which governs the expression of virulence determinants, including surface and exoproteins, while agr activity has been correlated with patient outcome and treatment efficiency. Here we describe a duplex real-time nucleic acid sequence-based amplification (NASBA) detection and quantification platform for rapid determination of agr functionality in clinical isolates. Using the effector of agr response, RNAIII, as the assay target, and expression of the gyrase gene (gyrB) as a normalizer, we were able to accurately discriminate agr functionality in a single reaction. Time to positivity (TTP) ratios between gyrB and RNAIII showed very good correlation with the ratios of RNAIII versus gyrB RNA standard inputs and were therefore used as a simple readout to evaluate agr functionality. We validated the assay by characterizing 106 clinical S. aureus isolates, including strains with genetically characterized agr mutations. All isolates with dysfunctional agr activity exhibited a TTP ratio (TTP gyrB /TTP RNAIII ) lower than 1.10, whereas agr-positive isolates had a TTP ratio higher than this value. The results showed that the assay was capable of determining target RNA ratios over 8 logs (10 ؊3 to 10 4 ) with high sensitivity and specificity, suggesting the duplex NASBA assay may be useful for rapid determination of agr phenotypes and virulence potential in S. aureus clinical isolates.
T
he Staphylococcus aureus accessory gene regulator (agr) locus, a well-studied quorum-sensing two-component regulatory system, is the central regulator within the overall staphylococcal virulon, which includes both secreted virulence factors and surface proteins. The agr locus is complex, consisting of two divergent transcriptional units, driven by promoters P2 and P3 (reviewed in reference 7). The P2 operon contains four genes (agrB, agrD, agrC, and agrA), coding for the following proteins: AgrC is the signal receptor and AgrA is the response regulator, while AgrB and AgrD combine to produce the activating ligand for AgrC. AgrA also activates the agr P3 promoter, which drives the synthesis of RNAIII, the effector of target gene regulation. RNAIII also encodes ␦-hemolysin, the expression of which serves as a surrogate for agr functionality (5, 18, 19) .
Animal studies have demonstrated that agr deficiency can attenuate Staphylococcus acute infections in a variety of models, including skin abscesses, endocarditis, septic arthritis, and osteomyelitis (reviewed in reference 7). Similarly, agr antagonists that block quorum sensing have anti-infective activity in experimental S. aureus infections (23) . Studies of agr activity from S. aureus isolates recovered from patients with ventilator pneumonia have shown that agr dysfunction is associated with improved patient outcomes (7) . However, S. aureus agr dysfunction has also been associated with longer duration of bacteremia and attenuated vancomycin bactericidal activity, as well as increased mortality among bacteremic patients (4, 13) . A number of reports have indicated that the emergence of vancomycin-intermediate S. aureus (VISA) was accompanied by agr dysfunction, mainly due to loss-offunction mutations within the agr operon (11, 12, 18) .
Although the virulence of agr mutants is attenuated in animal models, the role of agr in clinical infections has not been clearly defined. In order to address this issue, a rapid and specific detection assay to determine agr functionality in clinical isolates is needed. Currently, assays of agr functionality are mainly based on phenotypic detection of ␦-hemolysin, the translation product of RNAIII. A sheep blood agar (SBA) plate assay is used to score the synergistic hemolytic activity of ␦-hemolysin versus ␣-and ␤-hemolysins (14, 19) . While this phenotypic assay is easy to conduct, interpretation of results is subjective, and intra-and interlaboratory results may vary, especially for isolates with weak hemolytic activity. Additionally, phenol-soluble modulins (PSMs) other than ␦-hemolysin (also known as PSM-␥) also possess synergistic hemolytic activity (2) . Consequently, although the synergistic hemolytic reaction is a reliable indicator of agr functionality, it is not specific for the detection or quantification of ␦-hemolysin production (2) . To address these considerations, we report the development of a duplex real-time nucleic acid sequence-based amplification (NASBA) assay that is able to quantify agr levels in clinical isolates.
(This study was partially presented at the 2009 Annual Meeting of the Infectious Diseases Society of America.)
MATERIALS AND METHODS
Bacterial strains. The S. aureus strains selected for this study were acquired from the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) (http://www.narsa.net) or from the Public Health Research Institute (PHRI) Tuberculosis Center strain collection and include strains with sequenced genomes and well-characterized agr groups (NCTC 8325, USA300-FPR3757, N315, Mu50, MRSA252, MW2, RN6390, RN6607, RN8462, RN5881, and RN6911). Forty-eight non-S. aureus strains used for specificity testing were obtained from the American Type Culture Collection (ATCC) and the PHRI collection. A total of 106 well-characterized isolates, collected over a 6-month period from 12 New York City hospitals during May 1996 (10, 15) , were used to validate the application of the NASBA assay.
Culture conditions and total RNA isolation. S. aureus was subcultured from frozen stocks on Trypticase soy agar (TSA) plates, and a single colony was picked for liquid culture in Trypticase soy broth (TSB). Overnight cultures were subcultured in a 1:100 dilution of fresh TSB and grown with vigorous shaking (250 rpm) at 37°C. Cell growth was monitored by spectrometric readings at 600 nm.
Upon reaching an optical density (OD) of 1.0 (approximately 3 h after subculturing), bacterial cultures were collected and pelleted by centrifugation (16,000 ϫ g for 10 min at 4°C). Bacterial pellets were then treated with 100 g/ml lysostaphin (Sigma-Aldrich, St. Louis, MO) at 37°C for 30 min, and RNA was isolated using the RNeasy minikit (Qiagen, Valencia, CA), according to the manufacturer's instructions. An RNase-free DNase set (Qiagen, Valencia, CA) was used to remove potential DNA contamination.
Oligonucleotide primers and probes. The oligonucleotides used in this study are listed in Table 1 . RNAIII, the effector of the agr quorumsensing regulatory system, was used as a target for agr activity. Gyrase gene gyrB, widely used in S. aureus reverse transcription-PCR (RT-PCR) assays, was used as the normalizing gene. S. aureus-specific targets for RNAIII and gyrB molecular beacon and primer design were evaluated using online BLAST searches (http://blast.ncbi.nlm.nih.gov/). Primers RNAIII-P1 and RNAIII-P2 and molecular beacon RNAIII-MB (labeled with 5-carboxyfluorescein [FAM] fluorophore) were designed to amplify RNAIII RNA. Similarly, primers gyrB-P1 and gyrB-P2 and molecular beacon gyrB-MB (labeled with CAL Fluro Red 610 fluorophore), were used to amplify gyrB RNA. Primer sets RNAIII-it-P1/P2 and gyrB-it-P1/P2 were designed to generate in vitro transcription RNA standards (described below). Molecular beacon probes were designed according to guidelines described at http://www.molecular-beacons.org/. Potential crossreactivity among molecular beacons and primers in simplex and duplex NASBA assays was investigated using the Autodimer online tool (20) . The mfold-RNA and -DNA programs were used to predict the secondary structure of S. aureus RNA and molecular beacon probes, respectively (25) . Molecular beacon probes were purchased from Biosearch Technologies (Novato, CA) and purified by high-performance liquid chromatography (HPLC) as described elsewhere (22); oligonucleotide primers were ordered from Integrated DNA Technologies (Coralville, IA).
Synthesis and quantification of target RNA transcripts. The artificial target RNA fragments for RNAIII and gyrB were synthesized by in vitro transcription as previously described (24) . Primers used to generate specific PCR products as template for in vitro transcription are listed in Table  1 . Purified RNA targets were quantified using a Quant-iT RiboGreen RNA quantification kit (Molecular Probes, Invitrogen, Carlsbad, CA). Ten-fold dilutions of RNA standards were prepared from 10 7 to 10 1 copies/l and frozen at Ϫ80°C until use.
Duplex NASBA assay. Simplex and duplex NASBA assays were performed on a NucliSENS EasyQ analyzer (bioMérieux, Lyon, France), using the NucliSENS EasyQ basic kit version 2 (bioMérieux, Lyon, France) for amplification. Primer sets and molecular beacon sequences used for simplex and duplex NASBA reactions are shown in Table 1 . Each sample was amplified in a 10-l NASBA reaction mixture (half the volume recommended by the bioMérieux protocol), consisting of 5 l of NASBA reagent-primer mix, 2.5 l of RNA template, and 2.5 l of the enzyme mixture (avian myeloblastosis virus retrotranscriptase, RNase H, and T7 RNA polymerase). In the simplex NASBA assay, 0.2 M RNAIII and gyrB primers and 0.1 M RNAIII and gyrB molecular beacons were used. To obtain equal amplification efficiencies for both targets in the duplex NASBA assay, primer concentrations were further optimized, and half the amount of RNAIII primers was used. Briefly, a total volume of 5 l of reaction mixture containing 70 mM KCl, 0.1 M RNAIII primers, and 0.2 M gyrB primers was incubated with 2.5 l RNA template in the presence of 0.1 M each RNAIII and gyrB molecular beacons at 65°C for 2 min, in order to denature RNA secondary structure. The reaction mixture was subsequently cooled to 41°C for 2 min to anneal the primers before adding 2.5 l of the enzyme mixture. After gentle mixing by tapping followed by brief centrifugation, the reaction mixtures were incubated at 41°C (isothermal cycling conditions) for 90 min. All samples were tested in duplicate.
RNA quantification using the NASBA assay. Following amplification, a threshold was determined by setting the fluorescence emitted during the first 5 measurement points as background (21) . The time point at which a reaction exceeds the threshold by more than 1.25-fold is denoted the time to positivity (TTP). In the simplex assay, quantification capacity was assessed by plotting the TTP values against the logarithm of the number of target molecules in each standard series and then calculating the linear regression. For the duplex assay, different combinations of input ratios from 10 1 :10 7 to 10 7 :10 1 for RNAIII and gyrB RNA transcripts, respectively, were used to generate a standard curve (Fig. 1) . Using this approach, the ratio of RNAIII to gyrB in each sample could be extrapolated from the standard curves.
In this study, the TTP ratio (TTP gyrB /TTP RNAIII ) was introduced as a simple readout measurement to quantify agr activity, given the close correlation between TTP ratio versus the RNAIII and gyrB input ratios (Fig.  1) . Based on the cutoff values of the TTP ratios, S. aureus isolates could be assigned to different agr functionality groups.
Analytical specificity. The specificity of the real-time NASBA assay for bacteria and fungi was verified in in silico studies using online BLAST databases (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The analytical specificity of the duplex NASBA assay was initially tested using a number of S. aureus reference strains with sequenced genomes and different agr groups, including the following (GenBank accession number, agr group): NCTC 8325 (NC_007795, agr I), USA300-3757 (NC_007793, agr I), N315 (NC_002745, agr II), Mu50 (NC_002758, agr II), MRSA252 (NC_002952, agr III), MW2 (NC_003923, agr III), RN6390 (X52543, agr I), RN6607 (AF001782, agr II), RN8462 (AF001783, agr III), RN5881 (AF288215, agr IV), and RN6911 (agr-knockout strain). Species specificity was tested against a variety of non-aureus staphylococcal species, including S. epidermidis (n ϭ 4), S. haemolyticus (n ϭ 2), S. capitis (n ϭ 2), S. hominis (n ϭ 2), S. saprophyticus (n ϭ 2), S. lugdunensis (n ϭ 2), S. lentus (n ϭ 2), S. xylosus (n ϭ 2), S. pseudintermedius (n ϭ 2), S. sciuri (n ϭ 2), S. warneri (n ϭ 2), S. gallinarum (n ϭ 1), and S. succinus (n ϭ 1). In addition, the analytical specificity of this assay was tested against of a number of Grampositive and Gram-negative bacterial species, including Enterococcus spp. , and Escherichia coli (n ϭ 2). Four fungal strains (Candida albicans) were also included. All bacterial and fungal strains were selected from our previous studies (1, 17) . Statistical analysis. The statistical significance of differences in gene expression was determined using the t test (Prism; GraphPad, San Diego, CA). Differences were considered statistically significant at P Յ 0.05.
RESULTS

Analytical sensitivity of NASBA assay.
A series of NASBA primers and probes were initially designed and tested in a simplex NASBA assay and then targeted to RNAIII and various S. aureus control genes (data not shown). Two simplex NASBA assays with similar amplification efficiencies were chosen (slopes of Ϫ2.18 and Ϫ2.24, respectively), and 10-fold serial dilutions of in vitrosynthesized RNA templates from both targets (RNAIII and gyrB) were used to generate standard curves. Both assays revealed a clear linear relationship between logarithmic RNA inputs (10 1 to 10 7 copies/l) and TTP. The coefficients of determination (R 2 ) were 0.9935 and 0.9920 for RNAIII and gyrB, respectively. The quantification limits for RNAIII and gyrB were as low as 10 copies/l in each simplex NASBA assay, corresponding to 25 RNA copies per reaction. For duplex NASBA assays, different input combinations (10 1 to 10 7 copies/l) of RNAIII and gyrB RNA were analyzed, as shown in Fig. 1 . RNAIII/gyrB input ratios spanning 8 logs of both targets were then plotted against the TTP ratios of both genes (TTP gyrB /TTP RNAIII ). Logarithmic values of TTP ratios showed very good correlation with logarithmic values of RNAIII/gyrB input ratios, from 10 Ϫ3 :1 to 10 4 :1 (R 2 ϭ 0.9916, P Ͻ 0.001) (Fig. 1) . RNA ratios were therefore measured over an 8-log dynamic range, from Ϫ3 to ϩ4 log units of RNAIII versus gyrB RNA, with the lowest quantification limit of 10 copies/l for each target.
Analytical specificity of NASBA assay. The specificity of the assay was initially tested using RNA isolated from S. aureus strains with sequenced genomes and from control strains of all four agr groups (see Materials and Methods). Both RNAIII and gyrB amplification curves were observed in all S. aureus strains tested, except for strain RN6911, which only produced the gyrB amplification curve due to the absence of the agr locus (8) . Analysis of different staphylococcal species, including agr homolog-bearing species such as S. epidermidis and S. lugdunensis (3, 9) , as well as other Gram-positive and Gram-negative pathogens, showed no amplification for either RNAIII or gyrB. These experimental findings support the BLAST search results used in the design of primers and molecular beacons.
Analytical reproducibility. The reproducibility of the assay was measured by analysis of three independent RNA samples in three independent NASBA experiments. The three NASBA runs were performed on three different days using three different lot numbers of the NucliSENS EasyQ Basic kit version 2 (bioMérieux, Lyon, France) and tested in triplicate. Three different RNA samples at input ratios of 10 3 :1, 1:1, and 10 Ϫ3 :1 (RNAIII/gyrB) were evaluated for reproducibility, expressed as the coefficient of variation (CV) of the log 10 values of the concentration. The precision associated with each RNA ratio level (10 Ϫ3 , 10 0 , and 10
3
) was assessed by calculating the CV for each. The CVs within a single run ranged from 0.67 to 10.07%, whereas the CVs in different runs ranged from 0.87 to 12.00%, showing that the precision of the duplex NASBA assays was significant.
Validation of duplex NASBA assay. In a previous study, agr functionality among 269 single-patient MRSA isolates was determined by screening for synergistic and direct hemolysis (15) . All 269 isolates were previously genotyped by a combination of methods, including spa typing, SCCmec typing, and pulsed-field gel electrophoresis (PFGE) (1, 10, 16) . Although the majority of strains were deemed positive for ␦-hemolysin production (synergistic hemolysis), 40 strains were identified as nonhemolytic, while 13 exhibited a mixture of both hemolytic and nonhemolytic colonies (15) .
Further analysis of the 53 nonhemolytic isolates (mixtures had been further purified) by sequencing of the agrA and agrC regions identified various mutations in the agr locus, including frameshift indels (n ϭ 19), nonsense mutations (n ϭ 9), nonsynonymous changes (n ϭ 19), and genetic alterations in intergenic regions (n ϭ 3) (15) . Among the three remaining isolates, two showed no agr mutations, while the agr region from the third isolate could not be amplified. Detailed genotyping data (spa, SCCmec, and PFGE) of these nonhemolytic isolates have been published previously (15) . A total of 53 hemolytic strains from the same collection were selected as agr ϩ controls: 13 from the purified mixtures and 40 with spa types, SCCmec types, and PFGE profiles identical or highly related to those of the nonhemolytic strains.
The RNAIII duplex NASBA assay results are shown in Fig. 2 . The TTP ratios (TTP gyrB /TTP RNAIII ) in each mutation group (including frameshift, nonsense, nonsynonymous, intergenic, and unidentified mutations) of nonhemolytic strains (␦-hemolysin negative) were compared with those of their corresponding hemolytic controls (␦-hemolysin positive). Upon growing cultures in TSB to an optical density at 600 nm (OD 600 ) of 1.0, all hemolytic isolates in each mutation group had significantly higher TTP ratios (TTP gyrB /TTP RNAIII ) than the corresponding nonhemolytic groups (Fig. 2) (P Ͻ 0.001). All TTP ratios in the hemolytic group (mean Ϯ standard deviation [SD], 1.48 Ϯ 0.16) were above 1.10 (corresponding to an RNAIII/gyrB RNA ratio of 1:1), whereas the ratios in the nonhemolytic agr mutation groups (0.82 Ϯ 0.03) were mostly below 0.90 (corresponding to an RNAIII/gyrB ratio of 1:10) (Fig. 2) . Two isolates with nonsynonymous agr mutations (BK2345 and BK2489) exhibited an RNAIII/gyrB value greater than 1.10 ( Fig. 2) , despite being genotypically indistinguishable and harboring identical agr mutations (Phe¡Cys at amino acid [aa] 248 in AgrC) (15) . However, Northern blot and RT-PCR analyses confirmed these strains express RNAIII at a relatively lower level than their genotypically equivalent agr ϩ controls (data not shown). Exoprotein profiles of both isolates were also determined at various time points (t ϭ 0, 2, 4, and 6 h) (19) and displayed a delayed agr activation pattern (data not shown), as described previously (18, 19) . It is therefore suggested that this nonsynonymous mutation (Phe¡Cys at aa 248 in AgrC) does not inactivate the agr locus, but rather delays agr activation, which results in failure to translate ␦-hemolysin, leading to a nonhemolytic phenotype.
As mentioned above, 2 of the 53 nonhemolytic strains (BK2397 and BK2359) did not harbor identifiable mutations in the agr region, while in another nonhemolytic strain (BK2549), the agr region could not be amplified (15) . In this study, duplex NASBA assay results indicated that BK2397 and BK2359 were actually producing RNAIII transcripts (TTP gyrB /TTP RNAIII ϭ 1.45 and 1.25, respectively), in agreement with the agr sequencing results. Exoprotein profiles of these isolates were similar to those of their agr ϩ equivalents (data not shown), suggesting that BK2397 and BK2359 are agr functional. Strain BK2549 makes very little RNAIII at the level of nonhemolytic agr mutation groups (TTP gyrB / TTP RNAIII ϭ 0.78), presumably due to a large insertion or deletion in the agr region. RNAIII expression in these three isolates was confirmed by RT-PCR (data not shown), consistent with duplex NASBA assay results.
These results demonstrate that agr-positive isolates, including the 53 ␦-hemolysin-positive controls, as well as strains BK2345, BK2489, BK2397, and BK2359, exhibit higher TTP gyrB /TTP RNAIII ratios (Ͼ1.10) than agr mutant isolates (ratio, Ͻ0.90) (Fig. 2) . Based on these observations, a TTP ratio of 1.10 appears to be a sensitive and specific cutoff for agr functionality.
DISCUSSION
In this study, we developed a quantitative agr functionality assay that simultaneously measures RNAIII and gyrB mRNA in a singletube reaction using a real-time duplex NASBA method. In contrast to other agr quantification techniques, such as RT-PCR, NASBA-based RNA amplification is achieved in a homogeneous and isothermal manner, which obviates the need for a thermal cycler and may facilitate potential clinical use with the production of point-of-care devices in resource-poor settings. The advantage of the one-tube format is that assay variation attributable to the experimental procedure influences each target amplification in the same manner, thereby increasing reproducibility. In combination with standardized NASBA reagents (NucliSENS EasyQ basic kit), our duplex assay offers significant advantages for both intraand interlaboratory comparisons, as most assay parameters have been well established (primers and molecular beacons) and quality controlled (reagents). Moreover, the duplex format provides savings in materials, reagents, and hands-on time, thereby reducing overall costs.
In this study, the gyrB/RNAIII TTP ratio was used as a simple and accurate readout to quantify RNAIII expression levels. For example, a TTP ratio of 1.10 was successfully used as a cutoff value to quickly differentiate agr functionality. As shown in Fig. 3A , if TTP gyrB is lower than or similar to TTP RNAIII (ratio, Ͻ1.10), agr activity is demonstrably negative, whereas if TTP RNAIII is considerably lower than TTP gyrB (ratio, Ͼ1.10), agr activity is positive (Fig. 3B) . Such an algorithm allows for easy and rapid interpretation of results.
One limitation of this study is that we only evaluated RNAIII expression at a single time point (OD of 1.0 in TSB), whereas agr activation is time and population density dependent (6, 8) . Evaluation of RNAIII expression at multiple time points would better define the RNAIII transcription profiles and agr functionalitiese.g., early versus delayed agr activation (18, 19) ; however, such an approach is not practical for routine screening. Moreover, we successfully differentiated a variety of agr mutant isolates from their corresponding agr ϩ controls using an OD of 1.0 (Fig. 2) , suggesting that this OD is a highly reliable single time point to evaluate agr functionality in clinical isolates.
In conclusion, the duplex NASBA assay described in this study is a powerful tool for measuring agr functionality in S. aureus strains over a broad dynamic range with good precision and accuracy. Both the assay performance and simplicity of execution are highly desirable for routine screening and quantification of agr activity in clinical S. aureus isolates. Future plans for the assay FIG 2 RNAIII expression levels in 106 clinical S. aureus isolates. TTP ratios (TTP gyrB /TTP RNAIII ) of ␦-hemolysin-negative isolates with nonsynonymous changes (n ϭ 19), frameshift indels (n ϭ 19), nonsense mutations (n ϭ 9), and intergenic mutations (n ϭ 3), as well as those with no mutations identified (n ϭ 3), were compared with their corresponding genetically identical or closely related ␦-hemolysin-positive controls. ␦ϩ and ␦Ϫ, ␦-hemolysin positive and negative, respectively. Dotted lines indicate the TTP ratio cutoffs of 1.10 and 0.90, respectively. Short horizontal lines within each group of data points denote the mean of each group.
include optimizing the application directly in clinical specimens such as blood culture, as well as exploring the role of agr in different clinical infections. 
